Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement). New 171,000-square-foot San Diego headquarters, adding manufacturing cleanrooms and R&D capacity.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New 171,000-square-foot San Diego headquarters, adding manufacturing cleanrooms and R&D capacity
- Initial base rent approximately $958,000 monthly, with annual 3.0% increases and operating costs borne by Capricor
- 18-month full rent abatement plus six-month partial abatement, materially delaying cash rent obligations
- Lease commencement tied to Deramiocel FDA approval or December 31, 2026, with termination rights if approval is not received
- Approximately $958,000 security deposit, signaling a significant long-term facility commitment contingent on regulatory progress
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 incorporates Item 1.01, indicating any financial obligation stems from the material agreement described there
- Investors must review Item 1.01 for the underlying agreement and potential cash commitments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.